Benzinga··Vandana SinghNovo Nordisk's Wegovy Pill Lifts Profit Outlook as GLP-1 Dominance Expands
Novo Nordisk's Q1 sales of $15.17B beat estimates, with Wegovy pill reaching 2M prescriptions. Company raised 2026 guidance to $42.39-$46.24B; shares surged 7.11%.
LLYNVOGLP-1 drugsQ1 earnings